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INTRODUCTION
In the USA, bortezomib (VELCADE ® ) is approved for the treatment of multiple myeloma (MM), 1 and in the EU, bortezomib in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated MM who are not eligible for high-dose chemotherapy with bone marrow transplant. 2 Substantial efficacy has been demonstrated with bortezomib-melphalan-prednisone (VMP) combination regimens in three multicenter, phase 3 studies conducted in transplant-ineligible patients with MM, [3] [4] [5] [6] [7] [8] [9] [10] including VISTA, a global registration study, 3, 4, 10 and two subsequent national cooperative group studies in Italy (GIMEMA MM-03-05) 6, 7, 9 and Spain (GEM2005MAS65). 5, 8 Various dosing schedules of bortezomib 1.3 mg/m 2 were used in the VMP regimens in the VISTA, GIMEMA MM-03-05, and GEM2005MAS65 studies. VISTA employed a VMP regimen consisting of four 6-week cycles of twice-weekly (BIW) bortezomib dosing, followed by five 6-week cycles of once-weekly (QW) bortezomib dosing; no maintenance therapy was administered following completion of VMP therapy. 3 The GIMEMA MM-03-05 study initially used the same dosing schedule for VMP as in VISTA, but this was amended to nine 5-week cycles of QW bortezomib dosing to reduce the incidence of peripheral neuropathy; as in VISTA, no maintenance therapy was administered following VMP. 6 In the GEM2005MAS65 study, VMP treatment consisted of one 6-week cycle of BIW bortezomib dosing followed by only five 5-week cycles of QW bortezomib dosing; in contrast to VISTA and GIMEMA MM-03-05, patients could subsequently be randomized to receive maintenance therapy for up to 3 years consisting of intermittent bortezomib plus either thalidomide or prednisone. 5, 8 Patient-level data from the individual study databases were analyzed retrospectively to evaluate the cumulative dose of bortezomib received during VMP treatment, as well as the efficacy and tolerability of the respective VMP regimens. The aim of these novel cross-study analyses was to evaluate the optimal bortezomib dosing schedule for use in the VMP regimen. In addition, we considered the available data on bortezomib-based maintenance therapy, which was employed following VMP in the GEM2005MAS65 study, to address the utility of this treatment approach in the context of optimizing outcomes following front-line VMP therapy.
METHODS
Full methodology for these studies has been described elsewhere, [3] [4] [5] [6] [7] including the predefined primary and secondary endpoints of each trial. The ClinicalTrials.gov registration numbers are NCT00111319 (VISTA), NCT01063179 (GIMEMA MM-03-05), and NCT00443235 (GEM2005MAS65).
Patients
The three phase 3 studies included in these analyses employed generally similar eligibility criteria, 3, 5, 6 as described in the Online Supplementary Methods. Review boards at all participating institutions approved the studies, which were conducted according to the
Declaration of Helsinki and International Conference on Harmonization Guidelines for Good
Clinical Practice. All patients provided written informed consent.
VMP regimens and study designs
The VMP regimens used in the VISTA (N=340), 3, 4, 10 GIMEMA MM-03-05 (N=253), 6, 7, 9 and GEM2005MAS65 (N=130) 5, 8 studies are summarized in Table 1 . Bortezomib dose modifications were required in VISTA 3 and GEM2005MAS65 5 for prespecified hematologic and (grade 3/4) non-hematologic toxicities, and in GIMEMA MM-03-05 6 for grade 4 hematologic and grade 3/4 non-hematologic adverse events (AEs). Across all studies, bortezomib-induced peripheral neuropathy was managed according to established dose modification guidelines. 11, 12 For the purposes of these retrospective analyses, VMP treatment was considered in two phases: early induction cycles of VMP therapy, to represent the initial phase of treatment, followed by later cycles of VMP. As the main objective of these analyses was to evaluate the cumulative dose of bortezomib received during VMP treatment in each study, together with the efficacy and safety of these VMP regimens, data from the maintenance portion of the GEM2005MAS65 study 5, 8 were not included in the analyses of cumulative bortezomib dosing. Data on the bortezomib-thalidomide-prednisone (VTP) regimen from 
Assessments
Response and progression were assessed according to the European Group for Blood and Marrow Transplantation (EBMT) criteria 13 in VISTA (using a pre-specified computer algorithm to apply the EBMT criteria to response assessment data) and GEM2005MAS65, Bortezomib dosing data were collated from individual patient data and tabulated.
Statistical analyses
No inferential statistical comparisons between studies were conducted due to confounding factors and differences in median follow-up time preventing comparisons across protocols.
Propensity score methods were employed to evaluate the comparability of patients across studies using age, gender, and International Staging System (ISS) disease stage, and by examining propensity distributions graphically. Descriptive statistics for parameters within each study were derived using patient-level data and used to evaluate clinically meaningful similarities among and differences between the VMP regimens. Further details of statistical analyses are provided in the Online Supplementary Methods.
RESULTS

Patients
The demographics and baseline characteristics of patients receiving VMP in the VISTA, GIMEMA MM-03-05, and GEM2005MAS65 studies are summarized in Table 2 . The characteristics of the small subgroups of patients with high-risk cytogenetics are summarized in Online Supplementary Table S1 . Baseline characteristics are summarized using patientlevel data from each individual study database; characteristics that were not consistently collected across studies are not shown. Propensity score methodology showed that the patient populations appeared generally similar between studies, with similar patient distributions in a logistic model employing age, gender, and ISS score as variables (Online Supplementary Figure S1 ). As shown in Table 2 , the proportion of patients with ISS stage I MM was slightly lower in VISTA (19%) compared with GIMEMA BIW (26%), GIMEMA QW (29%), and GEM2005MAS65 (30%). In addition, VISTA was a global, international study, with patients enrolled from various regions, while the patients in the Italian GIMEMA MM-03-05 and Spanish GEM2005MAS65 studies were more homogeneous in this aspect.
Treatment exposure
As previously reported, patients received medians of 9, 9, 9, and 6 cycles of VMP therapy in VISTA, 4 GIMEMA BIW, 7 GIMEMA QW, 7 and GEM2005MAS65, 5 respectively. For bortezomib dosing during VMP treatment, the new analyses reported here showed that the proportion of patients receiving bortezomib for all planned VMP cycles (nine in VISTA and GIMEMA, six in GEM2005MAS65) was lower in VISTA (37.4%) versus GIMEMA BIW (58.7%), GIMEMA QW (65.3%), and GEM2005MAS65 (69.2%) ( Table 3 ). Rates of completion of early induction cycles (cycles 1-4 in VISTA and GIMEMA) were somewhat higher in GIMEMA BIW (74.6%) and QW (80.5%) compared with in VISTA (61.8%) ( Table   3 ).
The median cumulative dose of bortezomib received overall during VMP treatment in each study (i.e. excluding maintenance) and during early VMP induction cycles is also shown in However, the proportion of the planned bortezomib dose that was actually delivered during VMP treatment was highest in GEM2005MAS65 (90.4%) and GIMEMA QW (86.1%) compared with VISTA (57.0%) and GIMEMA BIW (62.3%). This was due to the lower number of bortezomib discontinuations and dose reductions required during VMP treatment in GEM2005MAS65 and GIMEMA QW (see Table 5 ). In VISTA, these dose modifications primarily occurred during the early cycles of VMP treatment; the frequencies of dose holds or reductions during cycles 1-9 were 47.4%, 54.5%, 57.3%, 52.3%, 28.2%, 16.4%, 20.3%, 20.4%, and 20.0% (Online Supplementary Figure S2 ). Reflecting these findings in the overall population, the proportion of planned bortezomib dose actually delivered in the small subgroups of patients with high-risk cytogenetics was also higher in GEM2005MAS65 (89.8%) compared with GIMEMA QW (79.7%) and GIMEMA BIW (73.7%), and compared with VISTA (51.9%) (Online Supplementary Table S2) .
Among all patients, in early VMP induction cycles, the median cumulative dose delivered , as would be expected. However, the proportion of the planned bortezomib dose that was actually delivered during this early phase of VMP induction was higher in GIMEMA QW (100%) and GEM2005MAS65 (90.4%) versus VISTA and GIMEMA BIW (both 71%). Subsequently, due to the impact of dose modifications in the early cycles, the proportion of the planned bortezomib dose that was actually delivered during later cycles (5-9) was lower in VISTA (60%) versus GIMEMA BIW (77%) and GIMEMA QW (90%). The same patterns were seen in the data for the small subgroups of patients with high-risk cytogenetics (Online Supplementary Table S2 ).
Comparison of efficacy between VMP regimens
Response rates and PFS and OS data for each of the phase 3 studies are summarized in Figure 1A , and indicate the apparent similarity in PFS between VISTA, GIMEMA BIW, and GIMEMA QW, and the apparent prolonged PFS in GEM2005MAS65.
Kaplan-Meier product-limit survival curves for OS for each study are shown in Figure 1B , and suggest similar OS across studies. OS rates at 3 years were high in all studies (67.9-75.7%; Table 4 ), with no substantial differences apparent, and rates at 5 years also appeared similar across the three studies with median follow-up >4 years (46.0-50.5%). It should be noted that OS may have been affected by regional variations in the availability of active novel-agent-based regimens as salvage, as well as by differences in median follow-up between studies.
Data on PFS and OS in the small subgroups of patients with high-risk cytogenetics are summarized in Online Supplementary Table S3 . PFS data in these patients appeared to generally reflect those for the overall populations, with medians appearing similar; as in the overall populations, median PFS appeared prolonged in GEM2005MAS65 (37.05 months), possibly associated with the use of bortezomib-based maintenance therapy. Data appear to suggest a generally shorter OS among patients with high-risk cytogenetics relative to the overall populations across the studies. Median OS (44.12-59.66 months) and 3-year rates (54.5-78.6%) appeared to vary across the studies, but comparisons are confounded by the small patient numbers.
Comparison of peripheral neuropathy and other aspects of safety between VMP regimens
Rates of peripheral neuropathy and discontinuations due to AEs with the VMP regimens are summarized in Table 5 . The grade 3/4 peripheral neuropathy rate was 13% in VISTA and 14% in GIMEMA BIW, but was reduced to 7% in GEM2005MAS65 and 2% in GIMEMA QW.
Similarly, discontinuations due to peripheral neuropathy were reduced in GIMEMA QW (4%) compared with VISTA (3% all treatment, 11% selective bortezomib discontinuation) and GIMEMA BIW (16%), as were bortezomib dose reductions due to peripheral neuropathy (14% versus 22% and 40%, respectively).
DISCUSSION
This analysis represents the first detailed evaluation and comparison of the three VMP regimens investigated in phase 3 studies to date, using the latest available patient-level data to evaluate consistently parameters and end points across studies. In particular, this is the first time that the same parameters, including bortezomib cumulative dose, proportion of planned dose delivered, and discontinuations, have been evaluated at the same time points across all three studies. It is also the first analysis to address these parameters across studies in the context of long-term outcomes, in particular 3-and 5-year OS rates, and with a detailed analysis of dose reductions and discontinuations due to peripheral neuropathy with the three VMP regimens.
The results of the phase 3 studies analyzed here show that the use of QW bortezomib dosing schedules in the VMP regimen in GIMEMA QW 7 and GEM2005MAS65 5 resulted in a similar cumulative dose of bortezomib and high efficacy with VMP treatment, comparable with that demonstrated in VISTA. 3, 4, 10 Across the studies, CR rates with VMP treatment appeared somewhat higher in VISTA 3, 4 and GIMEMA BIW, 7,9 but this did not appear to translate into differences in long-term OS, with 3-year rates of 67.9-75.7% and 5-year rates of 35.4-50.5% across studies. Median PFS also appeared similar across the VISTA and GIMEMA studies (21.75-25.23 months) but appeared higher in GEM2005MAS65 (38.05 months) likely due to the impact of up to 3 years' maintenance with bortezomib-based therapy, as discussed below. Notably, while the median cumulative doses of bortezomib administered during VMP treatment appeared similar across studies, particularly across those employing the same planned duration of treatment of 9 cycles, the proportion of the planned bortezomib dose actually delivered was higher with the QW regimens, thus counterbalancing the initially lower CR rate with these regimens versus the BIW regimens.
It is important to emphasize that comparisons across studies should be made with caution due to potential confounding factors, and that there are no randomized studies directly comparing BIW with QW bortezomib dosing in combination regimens, emphasizing the importance and relevance of this detailed analysis. While disease outcomes appeared similar across the studies, VISTA appeared to include a lower proportion of patients with ISS stage I disease and enrolled patients from various regions around the world; both of these factors may have had an effect on the findings. A formal meta-analysis or case-match analysis using these three studies of VMP was not feasible with the available data and was confounded by differences between studies in terms of length and frequency of follow-up.
However, using propensity score methodology, we demonstrated that the patient populations appeared generally comparable between studies, supporting the validity of the indirect, between-study comparisons reported here and the similar efficacy seen with BIW and QW bortezomib in the VMP regimen. Further, in the GIMEMA MM-03-05 study, a combined analysis of the VMPT and VMP arms demonstrated no significant difference in CR rates between patients receiving QW versus BIW bortezomib dosing in these regimens (30% vs 35%, P = .27), and no significant differences in 3-year PFS (50% vs 47%, P > .999) and OS (88% vs 89%, P = .54) rates. 7 Results from other smaller studies of QW bortezomib-based combination regimens in patients with previously untreated MM 16, 17 also support the similar efficacy with QW versus BIW bortezomib in the VMP regimen seen in the phase 3 studies analyzed here. Similarly, QW bortezomib dosing has been shown to offer notable efficacy in follicular lymphoma in combination with rituximab. 18, 19 However, it should not be assumed that these findings from the VISTA, GIMEMA MM-03-05, and GEM2005MAS65 studies employing VMP in elderly, transplant-ineligible patients may translate to induction therapy for younger, transplant-eligible patients. In this setting, further studies would be needed of QW bortezomib-based induction regimens to determine whether the reduced bortezomib dose density compared with BIW dosing in these shorter treatment courses had a detrimental impact on post-induction or post-transplant response rates and on post-transplant outcomes.
An important aspect of our findings was the apparently similar efficacy of VMP with BIW and QW bortezomib dosing in patients with high-risk cytogenetics. In general, the relative results between studies seen in the overall populations were reflected in these small subgroups of patients (n=15-33). Overall response rates appeared similar, while the CR rate appeared higher in VISTA, using the more intensive BIW bortezomib dosing regimen, compared with GEM2005MAS65 in particular, employing predominantly QW dosing for a total of only six induction cycles. However, median PFS in patients with high-risk cytogenetics appeared similar to that in the overall population, across all studies, with a similar PFS seen in VISTA, GIMEMA BIW, and GIMEMA QW, and a longer PFS in GEM2005MAS65, possibly associated with the use of bortezomib-based maintenance. OS appeared somewhat shorter in patients with high-risk cytogenetics versus the overall population, notably in VISTA and GEM2005MAS65, but the small patient numbers prevent any meaningful conclusions being drawn regarding whether the lower intensity QW bortezomib dosing regimens had a specific adverse effect in these patients. Contradictory results have been reported from the overall study populations, with no significant difference in OS reported between patients with highrisk versus standard-risk cytogenetics in GIMEMA MM-03-05, 9 but shorter OS reported in high-risk patients in VISTA and GEM2005MAS65. 10, 20 While activity appeared generally similar between VMP regimens in the present analysis, the rates of peripheral neuropathy and associated discontinuations and dose reductions were lower with VMP regimens using primarily QW bortezomib dosing, i.e. in GIMEMA QW and GEM2005MAS65. Notably, the rate of grade 3/4 peripheral neuropathy was reduced from 13% in VISTA 3,4,21 and 14% in GIMEMA BIW 7 (both incorporating four 6-week cycles of BIW dosing) to 7% in GEM2005MAS65 (one 6-week cycle of BIW dosing) 5 and 2% in GIMEMA QW (no BIW dosing). 7 Consequently, a higher proportion of the planned dose of bortezomib was actually delivered in GIMEMA QW and GEM2005MAS65 compared with VISTA and GIMEMA BIW. Moreover, the VISTA, GIMEMA BIW, and GIMEMA QW regimens delivered a similar median cumulative dose, as reflected in the comparable efficacy. The similar cumulative dose in VISTA and GIMEMA QW was due to the impact of bortezomib dose modifications that occurred primarily during cycles 1-4 in VISTA, i.e. the initial BIW cycles, as shown in Online Supplementary Figure S2 .
Importantly, a phase 3 trial in patients with relapsed MM has shown that subcutaneous administration of bortezomib on a standard BIW dosing schedule delivers an equivalent cumulative dose, and thus similar efficacy, to standard intravenous administration. 22 However, the subcutaneous route of administration was associated with a significantly lower rate of peripheral neuropathy, including 6% versus 16% grade ≥ 3 peripheral neuropathy. 22 Thus, switching from intravenous to subcutaneous administration may represent an additional strategy for managing toxicity in some patients while maintaining efficacy, and may improve convenience of therapy, particularly in elderly MM patients.
Maintenance therapy was employed following VMP in only one study (GEM2005MAS65).
Notably, in this study, the CR rate increased from 24% to 42% among patients receiving bortezomib-based maintenance using an intermittent dosing schedule (Table 1) , after a median follow-up of 46 months. 8 This translated into a prolongation of PFS, with a median of 35 months for the per-protocol population. 5 The use of bortezomib-based maintenance for up to 2 years was also shown to contribute to substantial efficacy following VMPT in the GIMEMA MM-03-05 study (from the landmark of completing VMPT or VMP therapy and proceeding to bortezomib-thalidomide maintenance or no maintenance, respectively, median PFS was 31.5 versus 17.8 months, and 4-year OS rate was 67% versus 55%, respectively). 6, 7, 9 However, the CR rate increased only from 58% to 62% among 62 patients who completed nine cycles of VMPT and then received at least 6 months of maintenance with bortezomib-thalidomide. 6 These data suggest that administration of bortezomib-based maintenance on an intermittent dosing schedule following truncated VMP induction may represent a valid approach to delivering sufficient cumulative dose of bortezomib to maximize response to treatment. 5, 8 Further support is provided by the findings of the HOVON-65/GMMG-HD4 phase 3 study in transplant-eligible MM patients, in which bortezomib maintenance resulted in increased response rates and a lengthy PFS following just three cycles of bortezomib-based induction and stem cell transplantation. 23 Importantly, in both GIMEMA MM-03-05 9 and GEM2005MAS65, 8 bortezomib-based maintenance therapy was well tolerated, with limited additional toxicity.
In conclusion, as has been well established based upon the results from VISTA, VMP can be BIW, twice-weekly; EU, European Union; ISS, International Staging System; QW, once-weekly; VMP, bortezomib-melphalan-prednisone Table 3 . Cumulative dose of bortezomib delivered, overall and as a percentage of the planned total dose, and rate of completion of all planned cycles and (for VISTA and GIMEMA MM-03-05) early cycles (1-4) of bortezomib (excluding maintenance therapy)
VISTA (N=340) GIMEMA BIW (N=63) GIMEMA QW (N=190) GEM2005MAS65 (N=130)
All VMP cycles 1-9 1-9 1-9 1-6* Table 1 , all 6 cycles in GEM2005MAS65 regarded as early cycles; QW, once-weekly; SD, standard deviation; VMP, bortezomib-melphalan-prednisone . 
ONLINE SUPPLEMENTARY METHODS
Patients
The three phase 3 studies included in these analyses employed generally similar eligibility criteria. 3, 5, 6 Patients with previously untreated MM and measurable disease who were ineligible for high-dose therapy and stem cell transplantation because of age (≥65 years) or coexisting comorbidities were enrolled. All patients had adequate hematologic and renal function. Patients with pre-existing grade ≥2 peripheral neuropathy or neuropathic pain were excluded. Review boards at all participating institutions approved the studies, which were conducted according to the Declaration of Helsinki and International Conference on
Harmonization Guidelines for Good Clinical Practice. All patients provided written informed consent.
VMP regimens and study designs
The VMP regimens used in the VISTA (N=340), 3, 4, 10 GIMEMA MM-03-05 (N=253), 6, 7, 9 and GEM2005MAS65 (N=130) 5, 8 studies are summarized in Table 1 on a weekly schedule (GIMEMA QW, N=190). In the GEM2005MAS65 trial, the first cycle comprised a 6-week cycle of BIW bortezomib as in VISTA, followed by five 5-week cycles of QW bortezomib; intermittent, bortezomib-based maintenance treatment could also be administered to patients in this study. 8 Bortezomib dose modifications were required in VISTA 3 and GEM2005MAS65 5 for prespecified hematologic and (grade 3/4) nonhematologic toxicities, and in GIMEMA MM-03-05 6 for grade 4 hematologic and grade 3/4 non-hematologic adverse events (AEs). Across all studies, bortezomib-induced peripheral neuropathy was managed according to established dose modification guidelines. 11, 12 For the purposes of these retrospective analyses, VMP treatment was considered in two phases: early induction cycles of VMP therapy, to represent the initial phase of treatment, followed by later cycles of VMP. As the main objective of these analyses was to evaluate the cumulative dose of bortezomib received during VMP treatment in each study, together with the efficacy and safety of these VMP regimens, data from the maintenance portion of the GEM2005MAS65 study 5, 8 were not included in the analyses of cumulative bortezomib dosing. Furthermore, in GEM2005MAS65 only 91 of 130 VMP patients were assigned to subsequent maintenance while the analyses presented in this paper are based on the total safety populations in each study. Nevertheless, we consider the data on maintenance in the Discussion section, in the context of the VMP cumulative bortezomib dosing analyses of the different VMP regimens. Data on the bortezomib-thalidomide-prednisone (VTP) regimen from GEM2005MAS65 5, 8 and on the VMP plus thalidomide (VMPT) regimen from GIMEMA MM-03-05 6,7,9 were also excluded. Our analyses specifically looked at differences between VMP regimens, and comparisons of neuropathy rates would be confounded by the added thalidomide in these regimens.
Assessments
Response and progression were assessed according to the European Group for Blood and Marrow Transplantation (EBMT) criteria 13 in VISTA (using a pre-specified computer algorithm to apply the EBMT criteria to response assessment data) and GEM2005MAS65, 
Statistical analyses
Propensity score methods were employed to evaluate the comparability of patients across studies using age, gender, and International Staging System (ISS) disease stage, and by examining propensity distributions graphically. Descriptive statistics for parameters within each study were derived using patient-level data and used to evaluate clinically meaningful similarities among and differences between the VMP regimens. 
